IGHE and Alzheimer disease: The overall ex vivo data exemplified with sera of patients with AD implies that, given a potent IgE neutralizer for treatment of IgE-sensitive allergic diseases, it remains a high-hurdle task to bring down the high serum-free IgE (and so allergen-specific IgE) close to a baseline, single-digit level if the steady, high IgE supply from neosynthesis could not be kept under effective control with measures in addition to simple neutralization of IgE.